Med Onc SpR @BartsHospital. Interested in IO, thoracic cancers, AI, and radiological biomarkers. NOTCH Chair @onctrainees. All views my own. He/Him.
Joined November 2022
- Tweets533
- Following471
- Followers162
- Likes4.2K
Alfred So retweeted
#EMUC26 in Brussels: Proud to see Jonas Repkewitz, our former lead resident doctor, present our IMPACT-UK multicentre study on triplet therapy in APMN/mHSPC. An outstanding clinician, researcher and rising oncologist! Do stop by our poster!
@BartsECMC @NHSBartsHealth
Alfred So retweeted
Surgery is SOC for operable early-stage NSCLC; VALOR may change that. Emulation can’t fully adjust for why SABR was chosen: often substantial comorbidity, frailty or limited physiologic reserve. Retrospective OPSCC studies reported better surgical OS; ORATOR didn’t @drdavidpalma
Alfred So retweeted
Non-randomized phase II study of neoadjuvant ivonescimab in pts with resectable NSCLC @NatureMedicine. Ivonescimab alone (n=10): MPR 60%, pCR 30%. Ivo + chemo (n=67) MPR 70%, pCR 51% (61% in squamous). Only 1 treatment related surgery delay.
nature.com/articles/s41591-0…
Another negative trial with concurrent RT and IO in NSCLC (this time in early stage I-II). Important to note that >80% were medically inoperable. Timing of IO with RT clearly matters here as with PACIFIC. For now SOC in medically operable patients is surgery until we have VALOR.
Remarkable results from SBRT +/- immunotherapy for unresected stage I-II NSCLC. No benefit from adding
IO & surgery remains standard of care for fit pts w stage I-II, EFS of ~30m w SBRT vs 46-65m for much more advanced disease in trials of neoadj IO #lcsm ascopubs.org/doi/10.1200/JCO…
Alfred So retweeted
I captured this video in my lab to show the power of medicines called T-cell engagers.
Left: T cells move in and out of a cancer tumoroid, largely ignoring it.
Right: Add a T-cell engager, and the T cells attack. Once they recognize their targets, they tear through the tumor.
Alfred So retweeted
🚨 Practice-changing KRAS G12C NSCLC #ESMO26
Divarasib may be the most potent inhibitor yet
📈 PFS: 9.8 vs 5.7m (HR 0.58)
📈 OS: 17.7 vs 12.0m (HR 0.56)
🎯 ORR: 58% vs 32%
Rapid 🇬🇧 reimbursement needed given challenges with sotorasib.
🔬 KRASCENDO-2 is OPEN at Barts!
Alfred So retweeted
New standard of care for KRAS G12C mutation positive NSCLC. @FSkoulidis presents Krascendo-1 head to head trial of divarasib vs sotorasib or adagrasib- convincing improving PFS (9.8 m vs 5.7 m, HR 0.58) and OS (17.7m vs 12.0m, HR 0.58)
Very well conducted study with hard to ignore results. Differences aren’t due to post-PD access. Definitely will change how we approach discussions with patients but I don’t think we can adopt a one-size-fits-all. Some patients still get excellent benefit from monotherapy.
Off the rousing #ESMO26 oral presentation from Dr. @decroisette, the phase III PERSEE trial with simultaneous publication @Annals_Oncology. Combination of chemotherapy + pembrolizumab superior to pembro in PDL1 high NSCLC: PFS 16.1 vs 6.9m, HR 0.56!
annalsofoncology.org/article…
Alfred So retweeted
#ESMO26 | PERSEE – Phase III
In advanced NSCLC with PD-L1 ≥50%, adding chemotherapy to pembrolizumab improved median PFS from 6.9 to 16.1 months (HR 0.56). The numerical OS difference was notable (50.2 vs 29.9 months; HR 0.77), but not statistically significant. However, we should remember that OS was not the primary endpoint!
Grade ≥3 toxicity: 53.8% vs 19.3%.
I think adding chemotherapy provides benefit, but at the cost of increased toxicity. We need to better identify the patients for whom this toxicity is worth it.
Alfred So retweeted
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial @atscommunity
academic.oup.com/ajrccm/arti…
Alfred So retweeted
Doctors are being bullied and discriminated against at work, but many do not think it is safe or worthwhile to report, a General Medical Council survey has found
bmj.com/content/395/bmj-2026…
Alfred So retweeted
Stephanie Saw (@stephanieplsaw) and colleagues found spread through air spaces in more than half of 378 resected stage 1 adenocarcinomas.
🔬 378 resected stage 1 adenocarcinomas, National Cancer Centre Singapore
📊 STAS in 54.2% of tumours, at similar rates in EGFR-mutant and wildtype disease
📊 STAS carried an adjusted HR of 2.32 for shorter DFS
📌 STAS-positive tumours carried more TP53 co-mutations and more whole genome doubling
Find the RNA sequencing subtypes behind those STAS-positive tumours in our article.
lungsummit.org/articles/spre…
Alfred So retweeted
New #JITC article: "Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses" doi.org/10.1136/jitc-2026-01…
Alfred So retweeted
Once in a while I get to read an article so good that I hope the rest of the world also reads it. Go home, drink the good wine, and read this. Superb editorial from @Prof_IanD : ascopubs.org/doi/10.1200/OP-…
Alfred So retweeted
Greg Videtic presents a 20+ year update from a registry with more than 1,100 pts comparing single vs multi-fraction lung SBRT for medically inoperable stage I NSCLC.
Alfred So retweeted
Excited to share our new @JTOonline publication on pulmonary toxicity from ADCs in lung cancer.
24 studies, 2,855 patients
🫁 Pneumonitis/ILD: 8.0%
⚠️ Grade ≥3 pulmonary AEs: 6.9%
Extremely grateful to @ChristianRolfo for his mentorship!
jto.org/article/S1556-0864(2…
@TischCancer
